Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series

Table 8 Medical cannabis effect on disability after 1, 3, and 12 months in Italian fibromyalgia patients

	Prior MC	With MC	P	Prior MC	With MC	P	Prior MC	With MC	P
ODI	1 month, n = 30			3 months, n = 18			12 months, n = 12
Median	64%	48%	< 0.01	68%	49%	< 0.01	61%	47%	< 0.01
IQR	28	23.5		25	29.5		25	40
Mean	64%	48%		68%	49%		61%	47%
± SD	17.8	19.1		18.5	21.7		18.3	22.2

IQR interquartile range, ± plus/minus, SD standard deviation, MC medical cannabis, ODI Oswestry Disability Index. The disability was measured with Oswestry Disability Index (ODI) in a cohort of 38 patients with fibromyalgia syndrome treated with medical cannabis at an Italian pain clinic. Wilcoxon signed-rank test was used to evaluate differences between time points

ISSN: 2522-5782